Bris­tol-My­ers claims the lead in a race to de­vel­op a TYK2 drug, hop­ing to dis­rupt a huge mar­ket for an­ti-in­flam­ma­to­ries

Bris­tol-My­ers Squibb’s TYK2 team has been show­ing off some Phase II da­ta they be­lieve puts them in the run­ning for leader of a small but promi­nent pack of de­vel­op­ers look­ing to ad­vance a new class of an­ti-in­flam­ma­to­ries that aim at pen­e­trat­ing some very big mar­kets.

As pub­lished in the New Eng­land Jour­nal of Med­i­cine and pre­sent­ed at the 27th Eu­ro­pean Acad­e­my of Der­ma­tol­ogy and Ven­erol­o­gy Con­gress in Paris, Bris­tol-My­ers’ ef­fort for BMS-986165 pro­duced some com­pet­i­tive re­sults in a key mid-stage study for mod­er­ate-to-se­vere plaque pso­ri­a­sis — a packed field where JAK in­hibitors have been mak­ing waves.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA